Pfizer Inc. (PFE)
| Market Cap | 135.09B |
| Revenue (ttm) | 63.83B |
| Net Income (ttm) | 10.75B |
| Shares Out | 5.69B |
| EPS (ttm) | 1.89 |
| PE Ratio | 12.57 |
| Forward PE | 8.46 |
| Dividend | $1.72 (7.24%) |
| Ex-Dividend Date | Jul 25, 2025 |
| Volume | 33,441,009 |
| Open | 23.73 |
| Previous Close | 23.60 |
| Day's Range | 23.61 - 23.81 |
| 52-Week Range | 20.92 - 30.43 |
| Beta | 0.46 |
| Analysts | Hold |
| Price Target | 29.36 (+23.57%) |
| Earnings Date | Nov 4, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for PFE stock is "Hold." The 12-month stock price target is $29.36, which is an increase of 23.57% from the latest price.
News
Pharma tariffs 'not a huge risk' for domestic companies, says Mizuho's Jared Holz
CNBC's “Fast Money” team discusses the potential impact of pharmaceutical tariffs with Jared Holz, healthcare equity strategist at Mizuho.
Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen
Courtney Breen, Bernstein senior analyst, joins 'The Exchange' to discuss the companies exempt from pharma tariffs, the country's with existing trade deals and much more.
Portal Innovations' John Flavin: Tariffs on pharma could raise costs and delay drug access
John Flavin, Portal Innovations founder and CEO, joins CNBC's 'Squawk on the Street' to discuss the Trump administration's proposed pharmaceutical tariffs, the impact on biotech startups and clinical ...
Eli Lilly, Pfizer Stocks Rise After Trump's 100% Pharma Tariff Threat. Here's Why.
Trump's threat of a 100% tariff on imported branded or patented drugs sounds dramatic, yet, pharma stocks were mostly in the green as the past few months have already seen a flurry of companies announ...
Hearing Against Pfizer Set For 29 September In Contraceptive ‘Depo-Provera' Multidistrict Litigation Overseen By Levin Papantonio
PENSACOLA, Fla.--(BUSINESS WIRE)--A hearing in the Depo-Provera legal action against Pfizer Inc. (NYSE:PFE) will take place on Monday, 29 September at 9:00am CT in the United States Courthouse in Pens...
Pfizer: Invest For The Yield, Not The Weight-Loss Drug Chase
Pfizer Inc. is acquiring Metsera for up to $7.2 billion, aiming to enter the weight-loss drug market despite late-stage entry and no ongoing Phase 3 trials. PFE's acquisition targets GLP-1-based obesi...
Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025
NEW YORK--(BUSINESS WIRE)--ESMO Curtain Raiser.
METSERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Metsera, Inc. - MTSR
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale Met...
Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, ...
This Hated Stock Suddenly Looks Like an Obesity Bargain
Pfizer's latest deal could make it the budget entry point to the weight-loss bonanza.
Final Trade: AAPL, C, PFE, KVUE
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Pfizer bets $7.3 billion on obesity drugs with Metsera buy
Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it's acquiring Metsera, and its portfolio of four medications fo...
BMO's Seigerman on Pfizer-Metsera deal: Bullish as we've waited on Pfizer's foray into obesity
Evan Seigerman, BMO Capital Markets head of healthcare research, joins 'The Exchange' to discuss Pfizer's obesity drug prospects, competitors and much more.
Pfizer Inc. (PFE) M&A Call Transcript
Pfizer Inc. (NYSE:PFE) M&A Call September 22, 2025 8:00 AM EDT Company Participants Francesca DeMartino - Chief Investor Relations Officer Chris Boshoff - Chief Scientific Officer and President of Re...
Johnson Fistel Investigates Fairness of Proposed Sale of Metsera
SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached th...
Wedbush Ups AAPL Price Target, PFE Acquires MTSR, Morgan Stanley Chip Upgrades
Wedbush continues to see tremendous upside for Apple (AAPL), citing iPhone sales and the new iPhone Air as catalysts. Pfizer's (PFE) acquisition of Metsera (MTSR) sent the obesity drug maker's stock s...
Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion Metsera Deal
Metsera (MTSR) shares skyrocketed 60% in premarket trading after Pfizer (PFE) agreed to purchase the biopharma firm for up to $7.3 billion to jump into the lucrative weight-loss drug segment. Shares o...
Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal
Pfizer Inc. PFE on Monday agreed to acquire Metsera, Inc. MTSR to accelerate the next generation of medicines for obesity and cardiometabolic diseases.
Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera
Pfizer said it would acquire weight loss biotech Metsera in a deal valued at up to $7.3 billion, including future payments, as it scrambles to win a slice in the booming obesity drug market. The move...
Pfizer makes a $4.9 billion bet on obesity drugs with Metsera buyout deal
Metsera's shareholders could see significant bonuses if certain milestones are reached.
Nasdaq 100 and S&P500: Intel Weakens, Metsera Spikes 59% on Pfizer Deal, Fed in Spotlight
Dow, S&P500 futures pull back today as Metsera pops 59%, Intel drops, and markets question whether Fed policy will match rate cut forecasts.
This Anti-Obesity Stock Jumps 60% on $7.3 Billion Bid by Pfizer
Pfizer said it would buy a clinical stage biopharma company for up to $7 billion, as it eyes the lucrative weight-loss drug market currently dominated by Eli Lilly and Novo Nordisk.
Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion
Pfizer has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera in a deal that gets the New York drugmaker back into the burgeoning market for obesity drugs.
Pfizer to buy weight-loss drug developer Metsera for up to $4.9 billion
Pfizer said on Monday it would acquire weight-loss drug developer Metsera for up to $4.9 billion to secure its position in the lucrative obesity treatment market.
Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Metsera, Inc. (NASDAQ: MTSR) today announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a cl...